| 20415-6 |
Choriogonadotropin.beta subunit |
ACnc |
Ser/Plas |
Pt |
Qn |
EIA.3rd IS |
|
ACTIVE |
Choriogonadotropin.beta subunit [Units/volume] in Serum or Plasma by Immunoassay (EIA) 3rd IS |
|
MIN |
DefinitionDescription |
|
|
mIU/mL |
|
|
|
|
|
|
CHEM |
|
20415-6 |
|
EIA.3rd IS |
|
|
Both |
|
|
|
0 |
B-HCG SerPl EIA 3rd IS-aCnc |
|
|
|
Y |
|
3IS; 3rd International Standard; 3rdIS; Arbitrary concentration; B; B HCG; Beta HCG; Beta human chorionic gonadotropin; B-HCG; CG; Chemistry; Choriogonadotropin beta chain; Choriogonadotropins total; Chorionic gonadotropin; EIA 3rd IS; HCG; Human chorionic gonadotropin; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tumor marker |
2.73 |
1.0m |
|
|
|
|
|
|
|
m[IU]/mL |
|
|
|
0 |
| 20416-4 |
Hepatitis C virus RNA |
NCnc |
Ser/Plas |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Hepatitis C virus RNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
copies/mL |
|
|
|
|
|
|
MICRO |
|
20416-4 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
HCV RNA # SerPl NAA+probe |
|
|
|
Y |
|
#; 3 Self-Sustaining Sequence Replication; 3SR SR; ABS; absolute; absolutes; Amplif; Amplification; Amplified; Cnt; Count; Count/volume; CT; DNA NUCLEIC ACID PROBE; DNA probe; HCV; Hep; Hep C; Hepatis; Hepatit; Hepatology; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Liver; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Number concentration; Number Concentration (count/vol); PCR; Pl; Plasma; Plsm; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; Ribonucleic acid; SDA; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Strand Displacement Amplification; TMA; Transcription mediated amplification; UniversalLabOrders; Viral load |
2.73 |
1.0m |
|
|
|
|
|
|
|
{copies}/mL |
|
|
|
0 |
| 20417-2 |
Histoplasma capsulatum mycelial phase Ab |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Histoplasma capsulatum mycelial phase Ab [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
20417-2 |
|
|
|
|
Both |
|
|
|
0 |
H capsul Myc Ab Titr Ser |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); H capsul; H capsul Myc; H capsulatum; H farciminosum; Histo; Histopl; Histoplasma farciminosum; Histoplasmin; Histoplasmos; Histoplasmosis; ID; Infectious Disease; InfectiousDisease; Microbiology; Mycel; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
1.0m |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 20418-0 |
Histoplasma capsulatum yeast phase Ab |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Histoplasma capsulatum yeast phase Ab [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
20418-0 |
|
|
|
|
Both |
|
|
|
0 |
H capsul Yst Ab Titr Ser |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); H capsul; H capsul Yst; H capsulatum; H farciminosum; Histo; Histopl; Histoplasma farciminosum; Histoplasmos; Histoplasmosis; ID; Infectious Disease; InfectiousDisease; Microbiology; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
1.0m |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 20419-8 |
Lutropin |
ACnc |
Ser/Plas |
Pt |
Qn |
1st IRP |
|
ACTIVE |
Lutropin [Units/volume] in Serum or Plasma by 1st IRP |
|
MIN |
DefinitionDescription |
|
|
mIU/mL |
|
|
|
|
|
|
CHEM |
|
20419-8 |
|
1st IRP |
|
|
Both |
|
|
|
0 |
LH SerPl IRP1-aCnc |
|
|
|
Y |
|
1st International Reference Preparation; Arbitrary Concentration; Chemistry; Endocrine; Endocrinology; First; ICSH; Interstitial cell-stimulating hormone; Interstitual cell stimulating hormone; IRP1; Leutinizing hormone; LH; Luteinizing hormone; Lutenin; Lutenizing hormone; Ovulation test; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1.0m |
|
|
|
|
|
|
|
m[IU]/mL |
|
|
|
0 |
| 2042-0 |
Carnitine.free (C0) |
PrThr |
Ser/Plas |
Pt |
Ord |
|
|
ACTIVE |
Carnitine free (C0) [Presence] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
2042-0 |
|
|
|
|
Both |
|
|
|
0 |
Carnitine Free SerPl Ql |
|
|
|
|
|
C0; Carnitine Free; Carnitine.total; Chemistry; FC; FR; Non-protein bound; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 20420-6 |
Acid phosphatase.prostatic |
MCnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Prostatic acid phosphatase [Mass/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
ug/L;ng/mL |
|
|
|
|
|
|
CHEM |
|
20420-6 |
|
|
|
|
Both |
|
|
|
0 |
PACP Ser-mCnc |
|
|
|
Y |
|
Ac Phos; Acd; Acid phosphatase.total; Acids; AcP; Chemistry; Level; Mass concentration; PACP; PAP; Phos; Phosphtase; Point in time; Prost; Prostate; Prostati; Prostatic ac phos; QNT; Quan; Quant; Quantitative; Random; Serum; SR; Tumor marker; UniversalLabOrders |
2.73 |
1.0m |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 20421-4 |
Barbiturates |
PrThr |
Ser/Plas |
Pt |
Ord |
Screen |
|
ACTIVE |
Barbiturates [Presence] in Serum or Plasma by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
20421-4 |
|
Screen |
|
|
Both |
|
|
|
0 |
Barbiturates SerPl Ql Scn |
|
|
|
|
|
Addiction; Barb; Barbiturate; Barbs; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Ordinal; Pl; Plasma; Plsm; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 20422-2 |
Alpha 1 antitrypsin |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated Alpha 1 antitrypsin [Mass/volume] in Serum or Plasma |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
20422-2 |
|
|
|
|
|
|
|
|
0 |
Deprecated A1AT SerPl-mCnc |
|
|
|
|
|
A1; A1A; A1AT; A-1-AT; A1-AT; AAT; Alfa; Alpha-1-antitrypsin.total; Alpha-1-protease inhibitor; Alpha-1-proteinase inhibitor; Alpha-1-trypsin inhibitor; Chemistry; i; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.36 |
1.0m |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 20423-0 |
Beta lactamase organism |
Prid |
Isolate |
Pt |
Nom |
|
|
ACTIVE |
Beta lactamase organism identified in Isolate |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
20423-0 |
|
|
|
|
Both |
|
|
|
0 |
B-Lactamase Organism Islt |
|
|
|
|
|
B; Betalactamase; B-Lactamase; B-Lactamase Organism; ID; Identity or presence; Infectious Disease; InfectiousDisease; Islt; Isol; Microbiology; Nominal; Point in time; Random; UniversalLabOrders |
2.79 |
1.0m |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by the coll w SCT:The understanding is that the word "identified" refers to the property "PRID", its presence in the component is redundant to the property. Therefore it is better to remove "identified" from the component.; |
0 |
| 20424-8 |
Cardiolipin Ab.IgG |
Imp |
Ser |
Pt |
Nom |
|
|
ACTIVE |
Cardiolipin IgG Ab [Interpretation] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
COAG |
|
20424-8 |
|
|
|
|
Observation |
|
|
|
0 |
Cardiolipin IgG Ser-Imp |
|
|
|
|
|
ABS; Aby; ACA; aCL; Antby; Anti; Antibodies; Antibody; Anticardiolipin; Autoantibodies; Autoantibody; Cardio; Cardiolip; Cardiolipn; Cardiolpn; CL; COAGULATION; Hematology; Heme; Immune globulin G; Immunoglobulin G; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Nominal; Point in time; Random; Serum; SR |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 20425-5 |
Cardiolipin Ab.IgM |
Imp |
Ser |
Pt |
Nom |
|
|
ACTIVE |
Cardiolipin IgM Ab [Interpretation] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
COAG |
|
20425-5 |
|
|
|
|
Observation |
|
|
|
0 |
Cardiolipin IgM Ser-Imp |
|
|
|
|
|
ABS; Aby; ACA; aCL; Antby; Anti; Antibodies; Antibody; Anticardiolipin; Autoantibodies; Autoantibody; Cardio; Cardiolip; Cardiolipn; Cardiolpn; CL; COAGULATION; Hematology; Heme; Immune globulin M; Immunoglobulin M; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Nominal; Point in time; Random; Serum; SR |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 20426-3 |
Alkaline phosphatase.bile |
CCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Alkaline phosphatase.bile [Enzymatic activity/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
arb U/L |
|
|
|
|
|
|
CHEM |
|
20426-3 |
|
|
|
|
Observation |
|
|
|
0 |
ALP Bile SerPl-cCnc |
|
|
|
Y |
|
Alk; Alk phos; Alkaline phos; Alkaline phosphatase biliary; Alkaline phosphatase.total; ALKP; ALP; ALP Bile; AP; Catalytic Concentration; Chemistry; Phos; Phosphtase; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.68 |
1.0m |
|
|
|
|
|
|
|
U/L |
|
|
|
0 |
| 20427-1 |
Acetylcholine receptor Ab |
SCnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Acetylcholine receptor Ab [Moles/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
nmol/L |
|
|
|
|
|
|
SERO |
|
20427-1 |
|
|
|
|
Both |
|
|
|
0 |
AChR Ab Ser-sCnc |
|
|
|
Y |
|
ABS; Aby; Acetylch; ACH; AChR; ACRA; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Level; Neuro; Neurology; Point in time; QNT; Quan; Quant; Quantitative; Random; Rec; Recept; Receptors; Recp; Recptr; Serology; Serum; SR; Substance concentration; UniversalLabOrders |
2.73 |
1.0m |
|
|
|
|
|
|
|
nmol/L |
|
|
|
0 |
| 20428-9 |
Phospholipid Ab.IgG |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Phospholipid IgG Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
COAG |
|
20428-9 |
|
|
|
|
Both |
|
|
|
0 |
Phospholipid IgG Ser Ql |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Antiphospholipid; aPA; APL; Autoantibodies; Autoantibody; COAGULATION; Hematology; Heme; Immune globulin G; Immunoglobulin G; Lipid; Ordinal; Phoslpd; Phospholipids; Pl; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 20429-7 |
Phospholipid Ab.IgM |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Phospholipid IgM Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
COAG |
|
20429-7 |
|
|
|
|
Both |
|
|
|
0 |
Phospholipid IgM Ser Ql |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Antiphospholipid; aPA; APL; Autoantibodies; Autoantibody; COAGULATION; Hematology; Heme; Immune globulin M; Immunoglobulin M; Lipid; Ordinal; Phoslpd; Phospholipids; Pl; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 2043-8 |
Carnitine.free (C0) |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
Carnitine free (C0) [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
2043-8 |
|
|
|
|
Both |
|
|
|
0 |
Carnitine Free SerPl-mCnc |
|
|
|
Y |
|
C0; Carnitine Free; Carnitine.total; Chemistry; FC; FR; Level; Mass concentration; Non-protein bound; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 20430-5 |
Culture medium |
Type |
Isolate |
Pt |
Nom |
|
|
ACTIVE |
Culture medium [Type] in Isolate |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
20430-5 |
|
|
|
|
Both |
|
|
|
0 |
Cult Medium Islt |
|
|
|
|
|
Cult Medium; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Microbiology; Nominal; Point in time; Random; Typ |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 20431-3 |
Observation |
Prid |
XXX |
Pt |
Nom |
Smear |
|
ACTIVE |
Microscopic observation [Identifier] in Specimen by Smear |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
20431-3 |
|
Smear |
|
|
Both |
|
|
|
0 |
Smear Spec |
|
|
|
|
|
ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Misc; Miscellaneous; Nominal; Other; Point in time; Random; smears; Spec; To be specified in another part of the message; UniversalLabOrders; Unspecified |
2.78 |
1.0m |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Updated to seperate the component from the method; |
0 |
| 20432-1 |
Epstein Barr virus nuclear Ab |
PrThr |
Ser |
Pt |
Ord |
IF |
|
ACTIVE |
Epstein Barr virus nuclear Ab [Presence] in Serum by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
20432-1 |
|
IF |
|
|
Both |
|
|
|
0 |
EBV NA Ab Ser Ql IF |
|
|
|
|
|
ABS; Aby; ACIF; ANA; ANF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Antinuclear antibody; Autoantibodies; Autoantibody; EBNA; EBV; EBV NA; Epstn; FA; FANA; Fluorescent antibody; Fluoresent; HHV-4; human herpesvirus 4; ID; IFA; Immune fluorescence; Immunoflour; Immunofluor; Immunofluorescence; Infectious Disease; InfectiousDisease; Microbiology; Mono; Mononucleosis; NA; Nuc; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR; Time Resolved Fluorescence; TRF |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 20433-9 |
Follitropin |
ACnc |
Ser/Plas |
Pt |
Qn |
2nd IRP |
|
ACTIVE |
Follitropin [Units/volume] in Serum or Plasma by 2nd IRP |
|
MIN |
DefinitionDescription |
|
|
mIU/mL |
|
|
|
|
|
|
CHEM |
|
20433-9 |
|
2nd IRP |
|
|
Both |
|
|
|
0 |
FSH SerPl IRP2-aCnc |
|
|
|
Y |
|
2nd International Reference Preparation; Arbitrary Concentration; Chemistry; Follicle stimulating hormone; FSH; IRP2; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Second; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1.0m |
|
|
|
|
|
|
|
m[IU]/mL |
|
|
|
0 |
| 20434-7 |
Prolactin |
ACnc |
Ser/Plas |
Pt |
Qn |
3rd IS |
|
DISCOURAGED |
Prolactin [Units/volume] in Serum or Plasma by 3rd IS |
|
MIN |
DefinitionDescription |
|
|
mIU/L |
|
|
|
|
|
|
CHEM |
|
20434-7 |
|
3rd IS |
|
|
Both |
|
|
|
0 |
Prolactin SerPl 3rd IS-aCnc |
|
|
|
Y |
|
3IS; 3rd International Standard; 3rdIS; Arbitrary concentration; Chemistry; Lactotropic hormone; Lactotropin; Mammatropic hormone; Mammotropin; Pl; Plasma; Plsm; Point in time; PRL; Prol; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1.0m |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 20435-4 |
Unidentified extractable nuclear Ab |
PrThr |
Ser |
Pt |
Ord |
Immune diffusion |
|
ACTIVE |
Unidentified extractable nuclear Ab [Presence] in Serum by Immune diffusion (ID) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
20435-4 |
|
Immune diffusion |
|
|
Both |
|
|
|
0 |
ENA Unident Ab Ser Ql ID |
|
|
|
|
|
ABS; Aby; ANA; ANF; Antby; Anti; Antibodies; Antibody; Antinuclear antibody; Autoantibodies; Autoantibody; ENA; ENA Unident; ID; Imm; Immunodiff; Immunodiffusion; Imun; Imune; NA; NOS AB; Nuc; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serology; Serum; SR |
2.56 |
1.0m |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 20436-2 |
Glucose^2H post dose glucose |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Glucose [Mass/volume] in Serum or Plasma --2 hours post dose glucose |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL.ROUTINE |
|
20436-2 |
|
|
|
|
Both |
|
|
|
0 |
Glucose 2h p Glc SerPl-mCnc |
|
|
|
Y |
|
120 min; 120 minutes; 120min; 2 hours; 2h p Glc; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Level; Mass concentration; p dose; p Glc; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; UniversalLabOrders |
2.73 |
1.0m |
|
|
|
|
|
|
|
mg/dL |
|
|
Changed Class from "CHAL" to "CHAL.ROUTINE" |
0 |
| 20437-0 |
Glucose^3H post dose glucose |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Glucose [Mass/volume] in Serum or Plasma --3 hours post dose glucose |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL.ROUTINE |
|
20437-0 |
|
|
|
|
Both |
|
|
|
0 |
Glucose 3h p Glc SerPl-mCnc |
|
|
|
Y |
|
3h p Glc; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Level; Mass concentration; p dose; p Glc; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1.0m |
|
|
|
|
|
|
|
mg/dL |
|
|
Changed Class from "CHAL" to "CHAL.ROUTINE" |
0 |
